Home > Analytics > GLAXOSMITHKLINE PHARMACEUTICALS

GLAXOSMITHKLINE PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 500660     NSE : GLAXO    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward
Pledged Shares : None or < 25%
Jul 16,2024
Price(EOD): ₹ 2,611.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 44,239.66 Cr
Value of ₹ 1 Lac invested in GLAXOSMITHKLINE PHARMACEUTICALS
on Jul 17,2019 (price: ₹ 1,183.05)

₹ 1 L

₹ 2.21 L

1W : 3.8% 1M : -2% 1Y : 83.1%
COMMUNITY POLL
for GLAXOSMITHKLINE PHARMACEUTICALS
Please provide your vote to see the results
GLAXOSMITHKLINE PHARMACEUTICALS is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best Quarterly Growth Mid Cap Stocks
Industry Peers & Returns1W1M1Y
GLAXOSMITHKLINE PHARMACEUTICALS 3.8% -2% 83.1%
SUN PHARMACEUTICAL INDUSTRIES -1.1% 4.2% 47.1%
CIPLA -0.1% -3.5% 48.3%
DR REDDYS LABORATORIES 0.8% 9.2% 30.9%
ZYDUS LIFESCIENCES 0.4% 6.9% 100.2%
DIVIS LABORATORIES -1.6% -0.5% 25.9%
MANKIND PHARMA -1.6% -5.6% 14.4%
TORRENT PHARMACEUTICALS 0.7% 3.2% 53%
LUPIN 1% 15% 94.9%

FUNDAMENTAL ANALYSIS OF GLAXOSMITHKLINE PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Mar2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 GLAXO is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF GLAXOSMITHKLINE PHARMACEUTICALS

 
Valuation Score
[As on : Jul 16,2024 ]

Ratio Consolidated
P/E
P/B
P/S
74.99
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 589.96 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

24.76
P/B Calculated based on Book Value of Rs 1,786.65 Cr
[Latest Year - Mar2024 - Consolidated Results ]

12.81
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 3,453.71 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 10% undervalued companies ! Discover More →

FAIR VALUE OF GLAXOSMITHKLINE PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
58%
55%
54%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF GLAXOSMITHKLINE PHARMACEUTICALS



GLAXOSMITHKLINE PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF GLAXOSMITHKLINE PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0
0
0
-
0
0
0
-
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF GLAXOSMITHKLINE PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF GLAXOSMITHKLINE PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
15.47%
17.98%
313.6%
325.37%
18.08%
51.56%
42.45%
45.75%
QtrlyTrend
8
Latest Qtr: Mar2024
Quarterly Result Analysis →


GLAXOSMITHKLINE PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE QUALITY 1.2% 5.1% 57.6%
S&P BSE HEALTHCARE 0.8% 4.7% 47.8%
S&P BSE 150 MIDCAP 0.7% 5.9% 61.6%
S&P BSE MOMENTUM 0.7% 6.6% 79.2%
S&P BSE 200 0.6% 4.9% 36.2%
NSE Indices1W1M1Y
NIFTY 500 0.6% 5.1% 39.4%
NIFTY LARGE MIDCAP 250 0.6% 4.9% 45.4%
NIFTY500 MULTICAP 50:25:25 0.5% 5.3% 46.7%
NIFTY MIDCAP150 0.5% 4.8% 58.5%
NIFTY MID SMALL400 0.5% 5.4% 60.4%

You may also like the below Video Courses


FAQ about GLAXOSMITHKLINE PHARMACEUTICALS


Is GLAXOSMITHKLINE PHARMACEUTICALS good for long term investment?

As on Jul 16,2024, the Fundamentals of GLAXOSMITHKLINE PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of GLAXOSMITHKLINE PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is GLAXOSMITHKLINE PHARMACEUTICALS UnderValued or OverValued?

As on Jul 16,2024, GLAXOSMITHKLINE PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS ?

As on Jul 16,2024, the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS is Rs. 1,681.52 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1,649.29
Fair Value [Median EV / Sales Model] : Rs. 1,681.52
Fair Value [Median Price / Sales Model] : Rs. 1,693.12
Estimated Median Fair Value of GLAXOSMITHKLINE PHARMACEUTICALS : Rs. 1,681.52

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is GLAXOSMITHKLINE PHARMACEUTICALS trading at a Premium or Discount?

As on Jul 16,2024, GLAXOSMITHKLINE PHARMACEUTICALS is trading at a Premium of 55% based on the estimates of Median Intrinsic Value!